Last Price
40.10
Today's Change
+0.445 (1.12%)
Day's Change
39.40 - 43.24
Trading Volume
182,011
Profile
NGNE
Exchange: NASDAQ Global Market NASDAQ Global Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Dr. Rachel L. McMinn Ph.D. Dr. Rachel L. McMinn Ph.D.
Full Time Employees: 91 91
IPO Date: 2014-03-07 2014-03-07
CIK: 0001404644 0001404644
ISIN: US64135M1053 US64135M1053
CUSIP: 64135M105 64135M105
Beta: 0.00 0.00
Last Dividend: 0.00 0.00
Dcf Diff: 29.37 29.37
Dcf: 10.29 10.29
Description
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Address
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
12
Apps
Top Articles
1
CEO Morning Brief
US Ordered TSMC to Halt Shipments of Chips for AI to China — Reuters
2
3
CEO Morning Brief
Dogecoin Outperforms Bitcoin as Trump Spurs Crypto Speculation
4
CEO Morning Brief
5
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
